SOURCE: MetaStat, Inc.

MetaStat, Inc. Logo

September 02, 2015 08:00 ET

MetaStat, Inc. Announces Positive Results of a MenaCalc™ Prognostic Study of Axillary Node-Negative Breast Cancer

Findings Reinforce the Value of MenaCalc™ as a Prognostic Marker for Survival in an Independent Patient Cohort and ANN Patient Population

BOSTON, MA--(Marketwired - September 02, 2015) - MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing tissue-based diagnostic tests for prediction of cancer metastasis, today announced positive results by Forse et al., published in BioMed Central Cancer of their MenaCalc assay in patients with axillary node negative (ANN) invasive breast cancer. Data from this study confirmed earlier results that MenaCalc™ is a strong predictor of disease-specific overall survival in patients with node-negative invasive breast cancer (p=0.0199), and had good performance in a subset of patients who did not receive hormone or chemotherapy (p=0.0052).

"This study further demonstrates the importance of the MenaCalc™ biomarker in predicting patient outcome in breast cancer patients and, importantly, in node-negative patients where physicians need the most information for determining proper treatment regimens," says Mark Gustavson, PhD, Vice President of Diagnostics for Metastat.

In this clinical study of 403 patients, 261 women received adjuvant treatment (chemotherapy and/or hormone therapy) and 142 did not. Women who had high MenaCalc™ scores had a 2.2-fold greater risk of death compared to patients with low MenaCalc™ (p=0.0199) when controlled for other traditional clinical factors. A similar association was found with the subgroup who did not receive adjuvant treatment (p=0.0353; n=142), but as expected, the association with patients who received adjuvant treatment was not significant, providing preliminary evidence that high MenaCalc™ patients may benefit from added therapy.

About MenaCalc™
MenaCalc™ is a quantitative immunofluorescent tissue-based assay which measures expression levels of the Mena protein and its non-invasive isoform Mena11A. The MenaCalc™ diagnostic platform is prognostic for metastatic risk and has the potential to predict outcome in multiple epithelial-based tumor types including breast cancer, prostate cancer, Non-Small Cell Lung Cancer (NSCLC), and colorectal cancer (CRC). The Mena protein and its isoforms are key potentiators and modulators of cellular phenotype and migration and are central to the metastatic cascade. Overexpression of MenaINVand down regulation of Mena11a in tumor cells correlate with increased metastatic potential. We believe MenaCalc™ predicts outcome and metastatic risk for the majority of invasive breast cancer patients including HER2-positive and Triple Negative (TNC) for which there is no viable diagnostic on the market currently.

About MetaStat, Inc.
MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company's function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat's testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston, MA.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

Contact Information